4.4 Pain Assessment, Analgesic Ladder & Palliative Care in Ghana

4.4 Pain Assessment, Analgesic Ladder & Palliative Care in Ghana

Quick Answer: Pain assessment is the fifth vital sign and relies on patient self-report as the clinical gold standard, utilizing validated instruments like the Numeric Rating Scale (0–10), the Wong-Baker FACES tool, or the behavioral FLACC scale for non-verbal patients. Pharmacological management follows the WHO Three-Step Analgesic Ladder: Step 1 (non-opioids ± adjuvants), Step 2 (weak opioids for moderate pain), and Step 3 (strong opioids like morphine for severe pain). Critical opioid safety requires tracking sedation levels using the Pasero scale—recognizing that sedation precedes respiratory arrest—and proactively managing opioid-induced constipation. In Ghanaian settings, palliative care unites symptom control with cultural sensitivity toward extended family communal autonomy and spiritual traditions surrounding death and bereavement.

---

Neurophysiology and Classification of Pain

Pain is defined by the International Association for the Study of Pain (IASP) as "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage." As clinical pioneer Margo McCaffery articulated: "Pain is whatever the experiencing person says it is, existing whenever they say it does."

The Neurobiological Pain Pathway

1. Transduction: Specialized peripheral sensory receptors (nociceptors) located in cutaneous, somatic, and visceral tissues detect noxious mechanical, thermal, or chemical stimuli. Damaged tissues release biochemical inflammatory mediators (prostaglandins, bradykinin, serotonin, substance P, histamine) that lower nociceptor activation thresholds.
2. Transmission: Action potentials propagate along primary afferent nerve fibers to the dorsal horn of the spinal cord (substantia gelatinosa):
   • A-delta (Aδ) Fibers: Lightly myelinated, rapid-conducting fibers that transmit sharp, localized, acute, stinging sensations.
   • C Fibers: Unmyelinated, slow-conducting fibers that transmit dull, aching, throbbing, chronic, burning sensations. Secondary projection neurons ascend via the spinothalamic tract to the thalamus and sensory cortex.
3. Perception: The conscious cognitive and emotional realization of pain within the somatosensory cortex and limbic system.
4. Modulation: Descending inhibitory neural pathways from the periaqueductal gray matter in the brainstem release endogenous opioid peptides (endorphins, enkephalins) and monoamines (serotonin, norepinephrine) down into the dorsal horn to attenuate nociceptive synaptic transmission.

Pain Classification Systems

                                  CLASSIFICATION OF PAIN
                                            |
                   +------------------------+------------------------+
                   |                                                 |
            BY DURATION                                          BY ETIOLOGY
    - Acute Pain: Sudden, identifiable cause,             - Nociceptive Somatic: Aching, sharp, localized
      sympathetic activation, healing resolves             - Nociceptive Visceral: Colicky, deep, poorly localized
    - Chronic Pain: >3-6 months, neuroplastic,            - Neuropathic: Burning, shooting, electric shock,
      no sympathetic signs, psychosocial impact             allodynia (nerve pathology)

• Acute Pain: Immediate onset following tissue injury or surgery. Accompanied by autonomic sympathetic activation (tachycardia, diaphoresis, hypertension, tachypnea, pupillary dilation). Resolves predictably with tissue healing.
• Chronic (Persistent) Pain: Extends beyond expected tissue healing time (typically > 3 to 6 months). The autonomic nervous system adapts (habituation), meaning vital signs often remain completely normal. Accompanied by neuroplastic remodeling, central sensitization, severe depressive disorders, anorexia, and social isolation.
• Nociceptive Somatic Pain: Originates in bone, joints, skin, and connective muscle tissues. Typically described as well-localized, sharp, throbbing, or aching (e.g., surgical incision, bone fracture).
• Nociceptive Visceral Pain: Originates from distension, ischemia, or inflammation of internal thoracic or abdominal organs. Typically described as diffuse, deep, cramping, or colicky, and frequently referred to dermatomal surface areas (e.g., hepatic capsule stretch, biliary colic).
• Neuropathic Pain: Generated by structural damage, compression, or pathological dysfunction of the peripheral or central nervous system. Characterized by burning, shooting, lancinating, electric shock-like sensations, tingling, paresthesia, and allodynia (pain provoked by a non-noxious stimulus, such as bedsheets touching skin). Examples include diabetic peripheral neuropathy, post-herpetic neuralgia, and phantom limb pain.

---

Validated Clinical Pain Assessment Scales

Systematic pain assessment must be conducted at triage, upon ward admission, prior to analgesic administration, at the peak onset of pharmacological effect (15–30 minutes post-IV; 30–60 minutes post-oral), and at every vital sign check.

1. Numeric Rating Scale (NRS) and Visual Analogue Scale (VAS)

• NRS (0–10): The patient rates pain intensity verbally on a scale where 0 represents "No Pain" and 10 represents "Worst Imaginable Pain" (1–3 = Mild; 4–6 = Moderate; 7–10 = Severe). Standard for cognitively intact adults and adolescents.
• VAS: A 10-cm horizontal line anchored with "No Pain" at 0 cm and "Worst Pain" at 10 cm. The patient marks a vertical point along the continuum, which the nurse measures with a ruler in millimeters.

2. Wong-Baker FACES Pain Rating Scale

Consists of six illustrated cartoon facial expressions ranging from a smiling, happy face (0 = "No Hurt") to a tearful, grimacing face (10 = "Hurts Worst").

• Clinical Value in Ghana: Highly effective in pediatric cohorts (≥ 3 years of age), elderly adults with mild cognitive impairment, and across diverse linguistic populations in Ghanaian regional hospitals (such as Twi, Fante, Ga, Ewe, Hausa, and Dagbani speakers) where English literacy or numeracy may be limited.

3. FLACC Behavioral Scale

Validated behavioral assessment tool for infants, young children under 3 years, and non-verbal, intubated, or critically ill patients unable to provide subjective self-report. Evaluates five behavioral categories, each scored from 0 to 2, yielding an aggregate score from 0 to 10:

---

The WHO Three-Step Analgesic Ladder

The World Health Organization (WHO) Analgesic Ladder established a global, evidence-based paradigm for managing acute, chronic, and oncological pain.

                                THE WHO ANALGESIC LADDER
                                           |
               +---------------------------+---------------------------+
               |                           |                           |
        STEP 1: MILD PAIN          STEP 2: MODERATE PAIN       STEP 3: SEVERE PAIN
          (NRS 1 - 3)                   (NRS 4 - 6)                (NRS 7 - 10)
    - Non-opioids: Paracetamol,    - Weak Opioids: Codeine,     - Strong Opioids: Morphine,
      NSAIDs (ibuprofen)             Tramadol, Dihydrocodeine     Fentanyl, Pethidine
    - +/- Adjuvants                - + Non-opioid (synergy)     - + Non-opioid
                                   - +/- Adjuvants              - +/- Adjuvants

Core Administration Principles

• "By the Mouth": The oral route is non-invasive, preserves patient dignity, and maintains steady serum levels; intramuscular injections should be avoided for chronic pain management.
• "By the Clock": Administer analgesics on a regular, scheduled round-the-clock basis for continuous pain rather than PRN ("as needed"). Add PRN fast-acting doses for "breakthrough pain."
• "By the Ladder": Advance sequentially from Step 1 to Step 3 if pain persists or intensifies.
• "For the Individual": Titrate the dosage against the patient's individual pain intensity and functional goals.

Detailed Pharmacological Steps and Adjuvants

1. Step 1 (Mild Pain: Score 1–3): Non-Opioid Analgesics:
   • Paracetamol (Acetaminophen): Centrally acting antipyretic/analgesic. Maximum adult daily dose is 4 grams/day (4,000 mg/24hr). Acute overdose causes fatal hepatic centrilobular necrosis, treated with IV N-acetylcysteine.
   • NSAIDs (Ibuprofen, Diclofenac): Inhibit cyclooxygenase (COX-1 and COX-2) enzymes, preventing peripheral prostaglandin synthesis. Excellent for inflammatory somatic pain. Risks: Gastric ulceration/bleeding, acute kidney injury, fluid retention, cardiovascular events.
2. Step 2 (Moderate Pain: Score 4–6): Weak Opioids:
   • Codeine, Dihydrocodeine, Tramadol: Tramadol exhibits dual action as a weak mu-opioid receptor agonist and a serotonin/norepinephrine reuptake inhibitor. Co-administered synergistically with Step 1 non-opioids.
   • Tramadol Warnings: Lowers seizure thresholds; risk of Serotonin Syndrome when combined with SSRIs or tricyclic antidepressants.
3. Step 3 (Severe Pain: Score 7–10): Strong Opioids:
   • Morphine: The international gold standard for severe cancer pain and acute post-trauma pain. Available in oral immediate-release solutions, sustained-release tablets, and subcutaneous/intravenous ampoules.
   • Fentanyl: Highly lipophilic synthetic opioid, 50–100 times more potent than morphine. Often preferred in renal impairment because it has no clinically significant active metabolites that accumulate.
   • Pethidine (Meperidine): Strictly contraindicated for chronic pain. Metabolized to normeperidine, a toxic metabolite with a long half-life that causes CNS excitation, tremors, hyperreflexia, and grand mal seizures, especially in renal dysfunction.
4. Adjuvant Medications (Co-Analgesics):
   • Anticonvulsants (Gabapentin, Pregabalin): First-line agents for neuropathic pain; block voltage-gated calcium channels in the spinal cord.
   • Tricyclic Antidepressants (Amitriptyline): Modulate descending noradrenergic pain-inhibitory pathways; highly effective in diabetic neuropathy and phantom limb pain.
   • Corticosteroids (Dexamethasone): Reduce peritumoral edema, relieve bone pain, and alleviate raised intracranial pressure or visceral capsular distension.

---

Opioid Safety: Sedation Monitoring, Naloxone Protocol & Bowel Regimens

While opioids are potent analgesics, safe administration requires active monitoring of adverse effects.

                                  OPIOID SAFETY TRIAD
                                           |
        +----------------------------------+----------------------------------+
        |                                  |                                  |
   SEDATION SURVEILLANCE           PROACTIVE BOWEL CARE               EMERGENCY REVERSAL
- Pasero POSS scale             - Tolerance NEVER develops!        - Naloxone (Narcan) titration
- Level 3: Unacceptable         - Mandatory co-prescription:       - 0.04 mg slow increments
- Level 4: Somnolent/Emergency    stimulant + stool softener       - Short half-life (30-90 min)
- Sedation precedes apnea         (e.g., Senna + Bisacodyl)          requires prolonged observation

The Pasero Opioid-Induced Sedation Scale (POSS)

Respiratory depression is almost universally preceded by increasing clinical sedation. Nurses must assess sedation status alongside respiratory rate:

• S: Sleep, easy to arouse.
• 1: Awake and alert.
• 2: Slightly drowsy, easily aroused; acceptable clinical sedation.
• 3: Frequently drowsy, drifts off to sleep during conversation; unacceptable. Nurse must withhold further opioid doses, notify prescriber, reduce opioid dose by 25%–50%, and maintain close surveillance.
• 4: Somnolent, minimal or no response to verbal/physical stimulation; emergency. Stop opioid immediately, call for rapid response, support airway, and initiate naloxone protocol.

Naloxone (Narcan) Titration Protocol

Naloxone is a pure, competitive mu-opioid receptor antagonist that immediately reverses opioid-induced respiratory depression and central sedation.

• Emergency Indication: Severe opioid overdose characterized by the Opioid Triad: respiratory depression (RR < 8–10 bpm or apnea), stupor/coma, and bilateral pinpoint (miotic) pupils.
• Administration Technique: Dilute a standard 0.4 mg (400 mcg) ampoule in 9 mL of sterile normal saline to yield 0.04 mg/mL (40 mcg/mL). Administer slowly IV in 0.04 mg (1 mL) increments every 2 to 3 minutes until the patient's respiratory rate improves to ≥ 10–12 bpm with adequate ventilation.
• Rationale for Titration: Rapid, undiluted IV push of 0.4 mg naloxone abruptly strips all opioid receptors, precipitating excruciating acute physical pain, violent sympathetic discharge, severe agitation, hypertensive crisis, pulmonary edema, and ventricular fibrillation.
• Half-Life Pharmacokinetics: Naloxone's half-life is 30 to 90 minutes, whereas therapeutic opioids (especially sustained-release morphine or methadone) have half-lives of 4 to 24 hours. The nurse must monitor the patient continuously for at least 2 to 4 hours, as the naloxone will wear off, allowing the patient to slip back into fatal respiratory depression.

Opioid-Induced Constipation (OIC) Management

Opioids bind directly to enteric mu-receptors in the bowel wall, inhibiting peristalsis, decreasing biliary/intestinal secretions, and increasing anal sphincter tone.

• Critical Concept: While patients rapidly develop pharmacological tolerance to opioid-induced nausea and sedation within 3 to 7 days, tolerance to opioid-induced constipation NEVER develops.
• Prophylaxis: A stimulating bowel regimen must be prescribed co-incident with the very first dose of regular opioid therapy. Administer a stimulant laxative (e.g., Senna, Bisacodyl) combined with an osmotic laxative / stool softener (e.g., Lactulose, Docusate sodium). Bulk-forming fiber laxatives (such as psyllium) are contraindicated because they can lead to impaction or mechanical bowel obstruction in the hypomotile opioid-inhibited gut.

---

Palliative Care Principles in Ghanaian Clinical & Community Settings

Palliative care is an approach that improves the quality of life of patients and their families facing life-threatening illness through the prevention and relief of suffering by means of early identification, comprehensive assessment, and treatment of pain and other physical, psychosocial, and spiritual difficulties.

Integration into Primary and District Healthcare

In Ghana, the burden of non-communicable diseases (advanced cervical, breast, and prostate malignancies, heart failure, end-stage kidney disease) and chronic infectious conditions (advanced HIV/AIDS) highlights the necessity of community-integrated palliative nursing. Palliative care is not restricted to the final days of terminal life; it begins alongside disease-modifying therapies at the time of serious diagnosis.

Cultural Realities and Family Dynamics in Ghana

1. Communal Autonomy & The Extended Family (Abusua): Unlike Western legal models emphasizing absolute individualistic autonomy, healthcare decision-making in Ghanaian communities is deeply communal. The extended family head (Abusua Panyin), elders, or spouse typically take a central role in clinical consultations. Nurses must navigate patient privacy with familial collectivism, facilitating inclusive family meetings.
2. Truth-Telling and Breaking Bad News: Families may request that clinicians withhold a terminal cancer prognosis from the patient to "prevent despair or loss of hope." Nurses should utilize structured frameworks like the SPIKES protocol (Setting, Perception, Invitation, Knowledge, Empathy, Strategy/Summary), gently exploring the patient's individual desire for disclosure while respecting cultural family hierarchies.
3. Spiritual and Religious Integration: In Ghana, illness and death are interpreted through deeply held Christian, Islamic, or traditional African religious worldviews. Many patients view terminal illness as a spiritual crisis, consulting traditional herbalists, spiritual prophets, or pastors concurrently. The palliative nurse must validate the patient's spiritual beliefs, facilitate pastoral or imam visits, support bedside prayer, and ensure clinical interventions do not needlessly disrupt sacred rituals.
4. End-of-Life Comfort and Bereavement: When active curative efforts cease, the nursing focus shifts entirely to dignified comfort care: maintaining oral hygiene, preventing pressure ulcers through frequent repositioning, managing dyspnea with low-dose oral morphine, relieving respiratory "death rattle" secretions with anticholinergics (glycopyrronium or hyoscine butylbromide), and providing compassionate bereavement support to the grieving family.